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Sarcoidosis is an uncommon systemic granuloma-
tous disease of unknown origin affecting lung, skin,
liver, and other tissues. Noncaseating granulomas in
the involved organs are the hallmark of this disease.
An exaggerated immune response to an unknown
antigenic stimulus could play a role in sarcoidosis
development.
Lung is one of the most frequently involved
organs.1 Manifestations range from alveolitis to
granulomatous infiltration of alveoli, bronchi, and
blood vessels. The end stage of lung sarcoidosis is
development of interstitial fibrosis with ‘‘honey-
combing’’ of lung parenchyma.
Interferon alfa in association with ribavirin is the
treatment of choice for hepatitis C. Early treatment of
acute hepatitis C with interferon alfa-2b will prevent
the development of hepatic cirrhosis, but adverse
effects are frequent and often can result in discon-
tinuation of treatment.2
Most frequent adverse effects related to interferon
are malaise, fever, arthralgia, and cough. Pulmonary
events such as bronchial asthma, bronchiolitis obliter-
ans, and interstitial pneumonitis have been reported.
Interferon alfa is also used in the treatment of
malignant melanoma, multiple myeloma, hairy-cell
leukemia and HIV-associated Kaposi’s sarcoma.3
Some cases of sarcoidosis after treatment with
interferon alfa have been reported in the literature.4-6
Improvement of sarcoidosis has been reported with
discontinuation of treatment, but in other cases an
independent course of disease has been proposed,
raising the belief that interferon discontinuation is
unnecessary in mild-to-moderate cases of interferon-
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m.We present the case of a patient with hepatitis C
treated with interferon in whom pulmonary
sarcoidosis developed. The sarcoidosis was initially
believed to be a pulmonary neoplasm, but skin
lesions developed that indicated the diagnosis of
systemic sarcoidosis. The sarcoidosis finally resolved
without discontinuation of interferon alfa.
CASE REPORT
A 50-year-old Romanian woman who was an
intravenous drug user and an active smoker had
hepatitis C and was started on a 48-week course of
interferon alfa-2a plus ribavirin. Thirty weeks after
initiating treatment, she presented to pneumology
department with a 3-week history of progressive
shortness of breath and hemoptysis. A chest radio-
graph showed bilateral hilar lymphadenopathy. A
lung neoplasm was suspected and computed to-
mography (CT) was performed showing enlarged
hilar lymph nodes and diffuse nodules affecting both
lungs (Fig 1, A). A positron emission tomography-CT
scan showed active absorption of fluorodeoxyglu-
cose at the lymph nodes and lung parenchyma
(Fig 1, B).
Subsequently, the patient had asymptomatic pap-
ules and nodules on the soles (Fig 2, A) and on a past
surgery scar (Fig 2, B). Biopsy of the skin lesions was
performed and showed epithelioid macrophages
converging in noncaseating naked granulomas
devoid of a conspicuous infiltrate of lymphocytesJAAD Case Reports 2016;2:146-9.
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Fig 1. Pulmonary sarcoidosis.A, CTscan shows gross bilateral hilar lymphadenopathy.B, PET-CT
shows absorption of fluorodeoxyglucose in the lymph nodes and lung parenchyma.
Fig 2. Cutaneous sarcoidosis. A, Skin-colored papules and nodules in the sole of the patient. B,
Nodule developed in the scar of a previous surgery.
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with the nuclei arranged in a peripheral circular
fashion (Fig 3). Special stains for acid-fast bacilli
and fungus were negative. No foreign material was
found with polarized light. No monoclonal proteins
were detected on serum protein electrophoresis.Angiotensin-converting enzyme level was elevated
at 128 IU/L. A transbronchial biopsy of the hilar
lymph nodes also found naked noncaseating
sarcoidal granulomas.
The patient was started on 30-mg daily of
prednisone for 8 weeks with progressive tapering.
Fig 3. Cutaneous sarcoidosis. Skin biopsy. A, Granulomatous infiltrate affecting the whole
dermis. B, Naked noncaseating granulomas without peripheral rim of lymphocytes (sarcoidal
granuloma). Inset, Langhans type multinucleated giant cell. (A and B, Hematoxylin-eosin stain;
original magnifications: A, 320; B, 340.).
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The skin lesions rapidly improved, and the dyspnea
resolved gradually. Interferon alfa and ribavirin
treatment was finished at week 48 with undetectable
hepatitis C virus RNA in her serum. The patient was
followed up for 6 months after finishing treatment,
and no recurrence of hepatitis C was noted. Skin
lesions and pulmonary symptoms did not recur.DISCUSSION
Several cases of interferon-induced sarcoidosis
have been reported in the medical literature. This
type of sarcoidosis can present from several days
after initiating treatment to years after completing
therapy.8,9
Diagnosis of sarcoidosis is given by the concur-
rence of characteristic skin findings or radiologic
findings and histopathologic findings of non-
caseating granulomas. Differential diagnosis of lung
sarcoidosis should be made with tuberculosis, some
fungal infections, berylliosis, and other interstitial
lung diseases.10 Skin lesions must be differentiated
from cutaneous Crohn’s disease, foreign body
reactions, leprosy, and cutaneous tuberculosis,
among others. Special stains and polarized light
examination must be performed to exclude other
entities, as sarcoidosis is a diagnosis of exclusion.10,11
The prognosis of interferon-induced sarcoidosis is
very good.2,7,11 Some investigators recommend
discontinuation of interferon therapy,4 but casesresolving in several months regardless of interferon
course have also been reported.7
Our patient responded very well to systemic
corticosteroids allowing treatment with interferon
to continue. This method of treatment can be
crucial in severe diseases that require interferon
for treatment such as hepatitis C or malignant
melanoma.CONCLUSION
Sarcoidosis should be suspected in a patient with
lung or skin disease while undergoing interferon alfa
therapy. Most cases are mild and prognosis is good.
Interferon alfa should be continued if there is no
life-threatening disease.
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